Christos Papadimitriou
Affiliations: | 2008 | University of Athens, Greece, Zografou, Greece |
Google:
"Christos Papadimitriou"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Emilios Theofanus Harlaftis | grad student | 2008 | University of Athens, Greece |
| Paul Laskarides | grad student | 2008 | University of Athens, Greece |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Vergote I, Perez Fidalgo A, Valabrega G, et al. (2024) ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society |
| Apostolou P, Dellatola V, Papadimitriou C, et al. (2021) Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects. Cancers. 13 |
| Fostira F, Papadimitriou M, Papadimitriou C. (2020) Current practices on genetic testing in ovarian cancer. Annals of Translational Medicine. 8: 1703 |
| Apostolou P, Fostira F, Kouroussis C, et al. (2020) BRCA1 & BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. International Journal of Cancer |
| Fountzilas E, Kotoula V, Koliou GA, et al. (2020) Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 11: 1-14 |
| Hardy-Bessard A, Moore KN, Mirza MR, et al. (2020) ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). Journal of Clinical Oncology. 38 |
| Koumarianou A, Makrantonakis P, Zagouri F, et al. (2020) Abstract P2-15-07: Real-world multicenter, prospective study of the effects of nab-paclitaxel on clinical outcomes and quality of life of patients with metastatic breast cancer in Greece. The ‘ABReast’ study Cancer Research. 80 |
| Fountzilas E, Konstantopoulou I, Vagena A, et al. (2019) Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clinical Breast Cancer |
| Fostira F, Kostantopoulou I, Apostolou P, et al. (2019) One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. Journal of Medical Genetics |
| Vagena A, Papamentzelopoulou M, Kalfakakou D, et al. (2019) PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. Journal of Human Genetics |